6th Mentored Paper (Summer 2022)
Topics
MPI6.1: Can the implementation of a machine learning model within a non-knowledge-based clinical decision support system be useful for front-line workers in psychiatry?
MPI6.2: How can innovative technologies in AI create a gold standard for disease modelling within psychiatry?
MPI6.3: What types of data (passive or actively gathered data) are useful for machine learning models in psychiatry (systematic/literature review)?
MPI6.4: What are some of the potential mechanisms for exercise to promote sleep?
MPI6.5: Why does exercise protect cognitive functions in aging?
MPI6.6: How will developments in artificial intelligence shape the future of organic chemistry?
MPI6.7: How can nanotechnology help in reaching United Nations (UN) sustainability goals?
MPI6.8: How do host microRNAs impact the gut microbiota during inflammatory bowel disease?
MPI6.9: What are the advantages and disadvantages of using microRNAs as either diagnostic or therapeutic tools for gut health and disease?
MPI6.10: As a society, how can we decrease the risk of developing cardiovascular disease?
MPI6.11: What therapeutic targets are used to combat cardiovascular disease?
MPI6.12: How do blood flow patterns affect genes, through epigenetics?
MPI6.13: What are the mechanisms/strategies for new drug therapies in cancer? How do emerging classes of cancer drugs compare to those currently available?
MPI6.14: What are the mechanisms of drug resistance in the treatment of cancer and what strategies are available to overcome this issue?
MPI6.15: What therapeutic opportunities are available in the tumour microenvironment?
MPI6.16: Why is measurable residual disease a useful prognostic factor in leukemia, and what methods are available for identifying measurable residual disease?
MPI6.17: What is the role of epigenetics in cancer?
MPI6.18: What are the short-term and long-term treatment-emergent adverse events and complications associated with cancer treatment?
MPI6.19: What therapeutic opportunities can you see in the tumour microenvironment?
MPI6.20: What is the potential for tumour subtyping to influence clinical practice?
MPI6.21: What are the origins of cancer-associated fibroblasts?
MPI6.22: Is a sex-specific approach to the management of type-2 diabetes warranted?
MPI6.23: What factors impact patient satisfaction in patient-healthcare provider interactions?
MPI6.24: What is the relationship between cholesterol/triglyceride levels and type-2 diabetes?
MPI6.25: What support strategies exist for caregivers of people with dementia?
MPI6.26: Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) fall under the category of Lewy body dementias; however the clinical and etiological distinction between PDD and DLB remain unclear. What are the morphological, neurophysiological, and/or cognitive/psychological differences that help distinguish between these two neurodegenerative disorders?
MPI6.27: Evidence suggests that age-related hearing loss is a risk factor for mild cognitive impairment and Alzheimer's disease, but the relationship between the two is unclear. What mechanisms are responsible for this relationship? How does age-related hearing loss interplay with the severity of memory and executive impairment in these populations?
MPI6.28: Research has suggested that early engagement in musical activities and learning a second language each serves as a protective factor for late-life neurodegenerative disorders. How does musicianship and bilingualism prevent and delay the progression of mild cognitive impairment and Alzheimer's disease/other dementias? (Alternatively, what is the evidence in incorporating music and/or language in cognitive interventions and rehabilitations for these populations?)
MPI6.29: Absolute pitch (i.e., perfect pitch) is the rare perceptual ability for musicians to automatically recognize and name a note without referring to a keyboard. What factors contribute to the development of absolute pitch, and what are the neurobiological underpinnings of this ability?
MPI6.30: What is the role of protein arginine methyltransferases in skeletal muscle? More specifically in response to exercise or in response to a disease that impacts skeletal muscle (ie. diabetes, cancer, neuromuscular diseases).
MPI6.31: What therapeutics and approaches are being developed to tackle the increasingly deadly rise in antibiotic-resistant pathogens (e.g. phage therapy, novel compounds)?
MPI6.32: How might “psychedelic” or naturally-occurring psychoactive substances (e.g. psilocybin, N, N-dimethyltryptamine) be applied to psychiatric treatment and/or addressing the current mental health crisis?
MPI6.33: What are the health and nutrient outcomes of incorporating more plant- protein in diet?
MPI6.34: How can myo-inositol and/or soy isoflavones be a putative approach for hyperandrogenism and insulin resistance in PCOS women?
MPI6.35: Is metformin use for PCOS women beneficial? And if so, what are the side effects?
MPI6.36: What are the effects of pea protein on postprandial responses of satiety and appetite?
MPI6.37: How can application of concepts of lifestyle medicine in clinical practice be beneficial for the promotion of health, prevention, and treatment of chronic diseases?
MPI6.38: How can you use nanoparticles to measure biomarkers for cancer?
MPI6.39: How can you use smartphones or microfluidics technology to make disease diagnostics more accessible to resource-limited settings?
